Company

Kaken Pharmaceutical Co. Ltd

Headquarters: Tokyo, Japan

Employees: 1,215

JPX: 4521 +0.53%

Market Cap

¥127.18 Billion

JPY as of Jan. 1, 2024

US$903.0 Million

Market Cap History

Kaken Pharmaceutical Co. Ltd market capitalization over time

Evolution of Kaken Pharmaceutical Co. Ltd market cap in the past 5 years

Market capitalizations are calculated from the opening stock price at the beginning of each month.

Market Cap History of Kaken Pharmaceutical Co. Ltd

Detailed Description

Kaken Pharmaceutical Co., Ltd. produces, markets, and sells medical products, medical devices, and agrochemicals in Japan and internationally. It offers pharmaceutical products and medical devices, such as Clenafin, a topical treatment for onychomycosis; Artz, an anti-osteoarthritis agent; Seprafilm, a semitransparent film-type absorbable adhesion barrier, which is applied to damaged tissue; Fiblast, a spray-on drug for the treatment of pressure ulcers and other skin ulcers; Regroth, a medicinal product for periodontal regeneration; and Hernicore for the treatment of lumbar disc herniation. The company also provides Adofeed, a pain- and inflammation-relieving plaster; Ebrantil for the treatment of dysuria and hypertension; Procylin, an oral-use prostaglandin I2 analog; Lipidil, an anti-hyperlipidemia agent; Mentax, an anti-trichophyton agent; and Loxoprofen Na Tape, a pain-relieving and anti-inflammatory plaster. In addition, it offers Ropion, a pain relief injection; and agrochemicals and animal health products, including Polyoxins that is used as fungicide; Pentoxazone, a rice herbicide; and Salinomycin, an anti-coccidial feed additive for chicken. Further, the company is developing BBI-4000 that has completed phase III clinical trial for primary axillary hyperhidrosis; KMW-1, which is in phase III clinical trial for the removal of eschar with thermal burns; KAR for treatment of hide lice infestation; and KP-607, which is in phase II clinical trial for the treatment of onychomycosis. Additionally, it is involved in the rental of Bunkyo Green Court, a commercial complex. The company offers its products under the Mentax Lotrimin Ultra, Mentax Butena, Mentax, Kaifen, Fiblast, and Jublia brands. It has license agreements with Corbus Pharmaceuticals Holdings, Inc. and Arbor Pharmaceuticals, LLC. Kaken Pharmaceutical Co., Ltd. was founded in 1917 and is headquartered in Tokyo, Japan.

Top 1-year algo backtest: +284.14%

$10,000 in April 2023 would now be $38,414 by following this algorithm daily at market close.

Boost your stocks returns with Disfold AI... Now!

Try Disfold AI for FREE

Stocks & Indices

Kaken Pharmaceutical Co. Ltd has the following listings and related stock indices.


Stock: JPX: 4521 wb_incandescent

Stock: OTC: KKPCF wb_incandescent

Details

Headquarters:

28-8, Honkomagome 2-chome

Bunkyo-ku

Tokyo, 113-8650

Japan

Phone: 81 3 5977 5001

Fax: 81 3 5977 5131